Name | Number of supported studies | Average coverage | |
---|---|---|---|
epithelial cell of proximal tubule | 8 studies | 40% ± 16% | |
hepatocyte | 5 studies | 33% ± 24% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
kidney | 3 studies | 23% ± 8% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
liver | 100% | 6517.62 | 226 / 226 | 89% | 72.60 | 363 / 406 |
kidney | 100% | 8580.15 | 89 / 89 | 64% | 18.00 | 573 / 901 |
pancreas | 100% | 216.81 | 328 / 328 | 1% | 0.94 | 2 / 178 |
stomach | 15% | 1.99 | 53 / 359 | 2% | 0.23 | 6 / 286 |
brain | 12% | 1.65 | 305 / 2642 | 0% | 0 | 0 / 705 |
adipose | 7% | 2.65 | 89 / 1204 | 0% | 0 | 0 / 0 |
peripheral blood | 5% | 2.36 | 50 / 929 | 0% | 0 | 0 / 0 |
spleen | 4% | 6.65 | 9 / 241 | 0% | 0 | 0 / 0 |
thymus | 3% | 0.65 | 21 / 653 | 0% | 0 | 0 / 605 |
intestine | 3% | 0.50 | 25 / 966 | 1% | 0.10 | 3 / 527 |
breast | 2% | 0.70 | 11 / 459 | 0% | 0.04 | 2 / 1118 |
esophagus | 1% | 0.29 | 16 / 1445 | 1% | 0.09 | 2 / 183 |
prostate | 2% | 0.19 | 4 / 245 | 0% | 0 | 0 / 502 |
uterus | 1% | 0.15 | 2 / 170 | 0% | 0.04 | 2 / 459 |
adrenal gland | 1% | 0.19 | 2 / 258 | 0% | 0.15 | 1 / 230 |
skin | 1% | 0.25 | 19 / 1809 | 0% | 0 | 0 / 472 |
blood vessel | 1% | 0.24 | 13 / 1335 | 0% | 0 | 0 / 0 |
lung | 1% | 0.07 | 3 / 578 | 0% | 0.11 | 4 / 1155 |
heart | 1% | 0.18 | 5 / 861 | 0% | 0 | 0 / 0 |
muscle | 0% | 0.04 | 3 / 803 | 0% | 0 | 0 / 0 |
ovary | 0% | 0 | 0 / 180 | 0% | 0.01 | 1 / 430 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bladder | 0% | 0 | 0 / 21 | 0% | 0 | 0 / 504 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 45 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0010133 | Biological process | proline catabolic process to glutamate |
GO_0006562 | Biological process | proline catabolic process |
GO_0005743 | Cellular component | mitochondrial inner membrane |
GO_0005739 | Cellular component | mitochondrion |
GO_0071949 | Molecular function | FAD binding |
GO_0004657 | Molecular function | proline dehydrogenase activity |
GO_0016645 | Molecular function | oxidoreductase activity, acting on the CH-NH group of donors |
Gene name | PRODH2 |
Protein name | Hydroxyproline dehydrogenase (HYPDH) (EC 1.5.5.3) (Kidney and liver proline oxidase 1) (HsPOX1) (Probable proline dehydrogenase 2) (EC 1.5.5.2) (Probable proline oxidase 2) Proline dehydrogenase (EC 1.5.5.2) |
Synonyms | HYPDH HSPOX1 |
Description | FUNCTION: Dehydrogenase that converts trans-4-L-hydroxyproline to delta-1-pyrroline-3-hydroxy-5-carboxylate (Hyp) using ubiquinone-10 as the terminal electron acceptor. Can also use proline as a substrate but with a very much lower efficiency. Does not react with other diastereomers of Hyp: trans-4-D-hydroxyproline and cis-4-L-hydroxyproline. Ubiquininone analogs such as menadione, duroquinone and ubiquinone-1 react more efficiently than oxygen as the terminal electron acceptor during catalysis. . FUNCTION: Converts proline to delta-1-pyrroline-5-carboxylate. . FUNCTION: Converts proline to delta-1-pyrroline-5-carboxylate. . |
Accessions | ENST00000588266.6 ENST00000589835.1 Q9UF12 K7EJK5 ENST00000653904.2 S4R3D8 ENST00000301175.7 |